Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

Table 3 Changes of ALT (IU/L) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated

	Crude model		Adjusted for baseline age, gender, ethnicity
	Coefficient β (95% CI)	p-value	Coefficient β (95% CI)	p-value
(Intercept)	30.182 (26.944, 33.421)	< 0.001	44.491 (35.438, 53.545)	< 0.001
Group	23.566 (17.691, 29.440)	< 0.001	21.868 (16.058, 27.677)	< 0.001
Time	−0.055 (− 0.169, 0.059)	0.346	− 0.055 (− 0.168, 0.059)	0.347
Group x Time ^a	− 0.562 (− 0.752, − 0.372)	< 0.001	−0.579 (− 0.768, − 0.390)	< 0.001

^a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. ALT Alanine aminotransferase; CI,confidence interval; TDF Tenofovir disoproxil fumarate

ISSN: 1471-2334